CN107849125A - 用于治疗靶向聚集的肽的创伤性脑损伤的方法 - Google Patents

用于治疗靶向聚集的肽的创伤性脑损伤的方法 Download PDF

Info

Publication number
CN107849125A
CN107849125A CN201680042690.4A CN201680042690A CN107849125A CN 107849125 A CN107849125 A CN 107849125A CN 201680042690 A CN201680042690 A CN 201680042690A CN 107849125 A CN107849125 A CN 107849125A
Authority
CN
China
Prior art keywords
peptide
brain injury
reagent
traumatic brain
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680042690.4A
Other languages
English (en)
Chinese (zh)
Inventor
拉尔斯·兰费尔特
汉斯·巴孙
埃里克·罗尔曼·瓦拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioarctic AB
Original Assignee
Bioarctic Neuroscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioarctic Neuroscience AB filed Critical Bioarctic Neuroscience AB
Publication of CN107849125A publication Critical patent/CN107849125A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680042690.4A 2015-07-21 2016-07-20 用于治疗靶向聚集的肽的创伤性脑损伤的方法 Pending CN107849125A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562195183P 2015-07-21 2015-07-21
US62/195,183 2015-07-21
US201662288813P 2016-01-29 2016-01-29
US62/288,813 2016-01-29
PCT/IB2016/054318 WO2017013599A1 (en) 2015-07-21 2016-07-20 Method for treatment of traumatic brain injury targeting aggregated peptides

Publications (1)

Publication Number Publication Date
CN107849125A true CN107849125A (zh) 2018-03-27

Family

ID=56550266

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680042690.4A Pending CN107849125A (zh) 2015-07-21 2016-07-20 用于治疗靶向聚集的肽的创伤性脑损伤的方法

Country Status (7)

Country Link
US (1) US11327080B2 (https=)
EP (1) EP3325506A1 (https=)
JP (2) JP2018522891A (https=)
CN (1) CN107849125A (https=)
AU (1) AU2016295650A1 (https=)
CA (1) CA2991856A1 (https=)
WO (1) WO2017013599A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069081A2 (en) * 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
CN101421303A (zh) * 2006-03-23 2009-04-29 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
CN103228674A (zh) * 2010-11-10 2013-07-31 霍夫曼-拉罗奇有限公司 用于神经疾病免疫疗法的方法和组合物
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
US20150004169A1 (en) * 2009-08-28 2015-01-01 The Board Of Regents Of The University Of Texas System Methods of Treating Brain Injury
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
US20150315267A1 (en) * 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006069081A2 (en) * 2004-12-22 2006-06-29 Washington University In St. Louis USE OF ANTI-Aβ ANTIBODY TO TREAT TRAUMATIC BRAIN INJURY
CN101421303A (zh) * 2006-03-23 2009-04-29 生命北极神经科学公司 改进的初原纤维选择性抗体及其用途
US20150004169A1 (en) * 2009-08-28 2015-01-01 The Board Of Regents Of The University Of Texas System Methods of Treating Brain Injury
CN103228674A (zh) * 2010-11-10 2013-07-31 霍夫曼-拉罗奇有限公司 用于神经疾病免疫疗法的方法和组合物
WO2013168174A1 (en) * 2012-05-08 2013-11-14 Ramot At Tel-Aviv University Ltd. Apoe4 antibodies for treatment of neurodegenerative conditions
WO2015035190A1 (en) * 2013-09-05 2015-03-12 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
US20150126390A1 (en) * 2013-09-12 2015-05-07 Washington University Multiplex avidity profiling of protein aggregates

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAGNONI SANDRA等: "New perspectives on amyloid beta dynamics after acute brain injury", 《ARCHIVES OF NEUROLOGY》 *
STINA TUCKERA等: "The Murine Version of BAN2401 (mAb158) Selectively Reduces Amyloid-Protofibrils in Brain and Cerebrospinal Fluid of tg-ArcSwe Mice", 《JOURNAL OF ALZHEIMER"S DISEASE》 *
张赛等主编: "《现代神经创伤及神经外科危重症》", 30 November 2010 *

Also Published As

Publication number Publication date
AU2016295650A1 (en) 2018-01-25
EP3325506A1 (en) 2018-05-30
US11327080B2 (en) 2022-05-10
JP2018522891A (ja) 2018-08-16
US20180209994A1 (en) 2018-07-26
WO2017013599A1 (en) 2017-01-26
CA2991856A1 (en) 2017-01-26
JP2022113682A (ja) 2022-08-04

Similar Documents

Publication Publication Date Title
Gasparotto et al. Receptor for advanced glycation end products mediates sepsis-triggered amyloid-β accumulation, Tau phosphorylation, and cognitive impairment
Li et al. Astrocyte-derived TNF-α-activated platelets promote cerebral ischemia/reperfusion injury by regulating the RIP1/RIP3/AKT signaling pathway
Zhang et al. Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases
Borlongan et al. Hibernation-like state induced by an opioid peptide protects against experimental stroke
CN107849125A (zh) 用于治疗靶向聚集的肽的创伤性脑损伤的方法
WO2020132045A1 (en) Inhibitors of sarm1 in combination with neuroprotective agents
AU2014223679B2 (en) Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
van Roon-Mom et al. Insoluble TATA-binding protein accumulation in Huntington’s disease cortex
US20140213526A1 (en) Small survival-promoting/immunomodulatory peptide for treatment of brain damage, neurodegenerative disorders, and inflammatory disorders
CN112079933A (zh) 一种多肽类似物及其在干预治疗脑出血药物中的应用
Zhang et al. SIRPα modulates microglial efferocytosis and neuroinflammation following experimental subarachnoid hemorrhage via the SHP1/STAT6 axis
Zhang et al. Astragaloside IV protects against autoimmune myasthenia gravis in rats via regulation of mitophagy and apoptosis
Duan et al. Endothelial EGLN3-PKM2 signaling induces the formation of acute astrocytic barrier to alleviate immune cell infiltration after subarachnoid hemorrhage
Wang et al. Montelukast sodium protects against focal cerebral ischemic injury by regulating inflammatory reaction via promoting microglia polarization
Xu et al. Spi1 aggravates neuropathic pain by modulating Clec7a-mediated neuroinflammation and microglial phagocytosis
Lapin et al. Extracellular CIRP dysregulates microglial efferocytosis in ischemic stroke via the TLR4/miR-155/MafB axis
CN104302666A (zh) 周围神经的IgG刺激髓鞘再生
Wang et al. Intracerebroventricular administration of lupus serum induces microglia activation and leukocyte adhesion in the cerebromicrovasculature of mice
Li et al. Physical exercise mitigates the cognitive impairments by promoting ER-phagy in mice model of Alzheimer's disease
Yu et al. Effect of mild hypothermia on glutamate receptor expression after status epilepticus
Zsigmond et al. Proteomic analysis of the cerebrospinal fluid in patients with essential tremor before and after deep brain stimulation surgery: a pilot study
CN107312071A (zh) 兴奋性神经毒性相关损伤的治疗方法
Wang et al. Fibrinogen drives neuroinflammation and neuropathology in perioperative neurocognitive disorders
Sung et al. P45 forms a complex with FADD and promotes neuronal cell survival following spinal cord injury
Luo et al. Effect of inducible co-stimulatory molecule siRNA in cerebral infarction rat models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Stockholm, Sweden

Applicant after: BIOARCTIC AB

Address before: Stockholm, Sweden

Applicant before: BIOARCTIC NEUROSCIENCE AB

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180327